Cancer Staging System

The AJCC has developed and compiled cancer staging references for quickly finding important information about different types of cancers. These references and tools are excellent resources for medical professionals treating patients with cancer.

Cancer Staging Resources


 8th Edition Updates and Corrections

When the AJCC embarked on updating the AJCC Cancer Staging Manual, we knew that we would have to think beyond the book, with an eye toward continuously improving content throughout the life of the edition. 

The delay of implementation to January 1, 2018 has given AJCC an opportunity to work with the surveillance community, the pathology community, and clinical decision support software developers in ways we never have before. In the era of electronic decision making, the level of scrutiny is higher; we are learning more about how the content is applied in different use cases beyond the human reader. Collaborating with these groups in real time has allowed us to take an extra critical look at our content and make improvements and clarifications that will help all audiences. 

This highly analytical effort has resulted in a greater number of updates and errata than in past editions, and we are committed to communicating them transparently. 

This site contains important updates and errata identified in the first printing of the AJCC Cancer Staging Manual, 8th Edition, and are effective for hard copy manuals purchased from September 2016 to present.  This list does not include typographical errors.  Updates and errata are tracked by staff and updated weekly. If you have identified any issues not listed here, please email



 AJCC Cancer Staging Form Supplement


January 1, 2018 is the new implementation date of the AJCC 8th Edition for cancer data collection.  As we work to align data collection standards with our member organizations, we will also improve the content of our staging form. 



 8th Edition Staging Rules


​In this resource, the rules and associated rationale are for the 8th Edition AJCC Cancer Staging Manual. Note that these are general rules described in Chapter 1 of the AJCC Cancer Staging Manual. Please refer to relevant disease site chapters to learn more about specific allowable disease site differences to correctly stage such patients and that are necessary for the appropriate medical care of the patient. 


 Chapter 1: Principles of Cancer Staging


​Chapter 1: Principles of Cancer Staging provides overall rules for AJCC cancer staging that apply across all tumor sites. In most cases, the rules are unchanged from previous versions of TNM; to the extent possible, ambiguities have been resolved. Although the rules generally apply across all disease sites, there are some exceptions as to how these rules are applied to specific disease sites. Wherever possible, such exceptions are noted, both in this chapter and in the appropriate disease site chapters.

chpater one button.png


 Supplementary Materials

​As part of the 8th Edition Project, authors were asked to develop content regarding three topics in cancer staging: 
  • Emerging Prognostic Factors for Clinical Care
  • Risk Assessment Models
  • Recommendations for Clinical Trial Stratification
Because of the rapidly-evolving nature of these topics, AJCC did not want to limit this information to the print manual where it would remain static for the life of the edition.  These topics are provided here, with the plan to update this information on a regular basis as the literature evolves.  Some of this information is incomplete, but it serves as a starting point for further study.


 Melanoma Prognosis


​​​We are pleased to offer you in this website​ the following prediction tools for predicting the clinical outcome of an individual patient with localized or regional cutaneous melanoma. The prediction tools can be used to predict the 1, 2, 5 and 10-year survival rates from initial diagnosis (with a 95% confidence interval) for an individual patient based on his/her relevant clinical and pathologic information. The predictive models were developed and validated using a combined database (n=28,047) from 11 major institutions and study groups participating in the development of the 7th edition of the American Joint Committee on Cancer (AJCC) Melanoma Staging System. This database includes 25,734 patients with localized melanoma and 2,313 patients with regional melanoma with relevant information available for model development. For detailed results regarding our prognostic factor analyses, model development and validation, please see the relevant manuscripts listed in the References section. Several additional useful prediction tools currently under development will be added to this website in the near future.